<table>
<thead>
<tr>
<th>Award Principal Investigator</th>
<th>Award Organization Name</th>
<th>Sponsor Name</th>
<th>Award Name</th>
<th>Award Status</th>
<th>Award Start Date</th>
<th>Award End Date</th>
<th>Funded Amount</th>
<th>Total Award Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abraham, Jerrold</td>
<td>110 Pathology</td>
<td>University of Illinois at Chicago</td>
<td>Characteristics of Dust and Risk Factors Associated with the Development of Rapidly Progressive Pneumoconiosis and Progressive Massive Fibrosis</td>
<td>ACTIVE</td>
<td>16-Jan-2018</td>
<td>15-Jan-2021</td>
<td>372,370.00</td>
<td>372,370.00</td>
</tr>
<tr>
<td>Agarwal, Rinki</td>
<td>110 Ob/GYN</td>
<td>Health Science Center Foundation at Syracuse</td>
<td>Establish FOX ovarian cancer models to test novel nanotherapeutics</td>
<td>ACTIVE</td>
<td>01-Jan-2018</td>
<td>31-Dec-2018</td>
<td>25,000.00</td>
<td>25,000.00</td>
</tr>
<tr>
<td>Bogart, Jeffrey</td>
<td>110 Radiology Oncology</td>
<td>Alliance Foundation Trials LLC</td>
<td>Phase II trial of induction immunotherapy with anti-PD-L1 for PD-L1 positive patients with unresectable stage IIIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent</td>
<td>ACTIVE</td>
<td>12-Oct-2017</td>
<td>11-Oct-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Bournopoulia, Dimitra</td>
<td>110 Surgery - Urology</td>
<td>Health Science Center Foundation at Syracuse</td>
<td>Targeting extracellular signaling in cancer</td>
<td>ACTIVE</td>
<td>01-Jan-2018</td>
<td>31-Dec-2018</td>
<td>5,000.00</td>
<td>5,000.00</td>
</tr>
<tr>
<td>Bradshaw, Deborah</td>
<td>110 Neurology</td>
<td>Cytokinetics Incorporated</td>
<td>A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CX 2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)</td>
<td>ACTIVE</td>
<td>17-Sep-2017</td>
<td>16-Sep-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Bratslavsky, Gennady</td>
<td>110 Surgery - Urology</td>
<td>MD Health Incorporated</td>
<td>Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study</td>
<td>ACTIVE</td>
<td>18-Sep-2017</td>
<td>17-Sep-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Carney, Barbara</td>
<td>110 Nursing</td>
<td>Health Resources and Services Admin</td>
<td>Behavioral Health Workforce Education and Training (BHWET) Program</td>
<td>ACTIVE</td>
<td>30-Sep-2017</td>
<td>31-Aug-2018</td>
<td>432,629.00</td>
<td>1,847,192.00</td>
</tr>
<tr>
<td>Chan, Gary</td>
<td>110 Microbiology</td>
<td>Carol M. Baldwin Breast Cancer Research Fund Inc</td>
<td>The metastatic potential of cytomegalovirus and breast cancer</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2019</td>
<td>50,000.00</td>
<td>50,000.00</td>
</tr>
<tr>
<td>Comito, Melanie</td>
<td>110 Pediatrics</td>
<td>St Baldrick's Foundation</td>
<td>St. Baldrick's Infrastructure Grant 2017</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>58,075.00</td>
<td>58,075.00</td>
</tr>
<tr>
<td>Domachowski, Joseph</td>
<td>110 Pediatrics</td>
<td>Leidos</td>
<td>A Phase 2/2b, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents</td>
<td>ACTIVE</td>
<td>02-Oct-2017</td>
<td>01-Oct-2018</td>
<td>105,219.84</td>
<td>105,219.84</td>
</tr>
<tr>
<td>Faraone, Stephen</td>
<td>110 Psychiatry</td>
<td>Shire Pharmaceutical Development Limited</td>
<td>Developing Quality Measures for Adult Attention Deficit Hyperactivity Disorder</td>
<td>ACTIVE</td>
<td>16-Oct-2017</td>
<td>15-Oct-2018</td>
<td>75,000.00</td>
<td>75,000.00</td>
</tr>
<tr>
<td>Faraone, Stephen</td>
<td>110 Psychiatry</td>
<td>Shire Pharmaceuticals</td>
<td>Web-Based Continuing Medical Education Program about Screening for Attention Deficit Hyperactivity Disorder (ADHD) in Adults</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>491,262.00</td>
<td>491,262.00</td>
</tr>
<tr>
<td>Fechtner, Robert</td>
<td>110 Ophthalmology</td>
<td>Research to Prevent Blindness</td>
<td>RPB Unrestricted Grant 2018</td>
<td>ACTIVE</td>
<td>01-Jan-2018</td>
<td>31-Dec-2018</td>
<td>115,000.00</td>
<td>115,000.00</td>
</tr>
<tr>
<td>Fortner, Christopher</td>
<td>110 Pediatrics</td>
<td>Vertex Pharmaceuticals Incorporated</td>
<td>A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ixazofil in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR . . .</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>2,000.00</td>
<td>2,000.00</td>
</tr>
<tr>
<td>Hehney, Heidi</td>
<td>101 Cell &amp; Developmental Biology</td>
<td>US Army Medical Research Acquisition Activity</td>
<td>PKS1 Spatial Synchronization in prostate epithelial cells during mitosis</td>
<td>ACTIVE</td>
<td>01-Aug-2017</td>
<td>31-Jul-2018</td>
<td>121,336.00</td>
<td>121,336.00</td>
</tr>
<tr>
<td>Horton, Jason</td>
<td>110 Surgery - Orthopedics</td>
<td>Carol M. Baldwin Breast Cancer Research Fund Inc</td>
<td>Role of marrow adiposity in skeletal metastasis of breast cancer</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>50,000.00</td>
<td>50,000.00</td>
</tr>
<tr>
<td>Huang, Dongmei</td>
<td>110 Pediatrics</td>
<td>Sanofi US Services Incorporated</td>
<td>An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (doxicamferol capsules) in Pediatric Patients with Chronic Kidney Disease Stages 3 and 4 with Secondary Hypoparathyroidism Not Yet on Dialysis</td>
<td>ACTIVE</td>
<td>13-Sep-2017</td>
<td>12-Sep-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Karimi, Mobin</td>
<td>110 Microbiology</td>
<td>National Institute of Allergy &amp; Infectious Disease</td>
<td>Novel strategies to separate GVHD from GVT</td>
<td>ACTIVE</td>
<td>21-Aug-2017</td>
<td>31-Jul-2018</td>
<td>162,000.00</td>
<td>266,383.00</td>
</tr>
<tr>
<td>Knutson, Bruce</td>
<td>110 Biochemistry</td>
<td>Carol M. Baldwin Breast Cancer Research Fund Inc</td>
<td>Targeting Pol 1 transcription in breast cancer</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>50,000.00</td>
<td>50,000.00</td>
</tr>
<tr>
<td>Kotula, Leszek</td>
<td>110 Surgery - Urology</td>
<td>Carol M. Baldwin Breast Cancer Research Fund Inc</td>
<td>Ab15 in breast Ca metastases and anti-HER2 therapies</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2018</td>
<td>50,000.00</td>
<td>50,000.00</td>
</tr>
<tr>
<td>Lavelle, William</td>
<td>110 Surgery - Orthopedics</td>
<td>Empirical Spine Incorporated</td>
<td>A Concurrently Controlled Study of LimFloX(TM) Parapineal Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis with Spinal Stenosis</td>
<td>ACTIVE</td>
<td>21-Sep-2017</td>
<td>20-Sep-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Lax, Michael</td>
<td>110 Family Medicine</td>
<td>NYS Department of Labor</td>
<td>Worker Healthy &amp; Safety</td>
<td>ACTIVE</td>
<td>01-Nov-2017</td>
<td>31-Mar-2018</td>
<td>200,000.00</td>
<td>200,000.00</td>
</tr>
<tr>
<td>Mollapour, Mehdi</td>
<td>110 Surgery - Urology</td>
<td>Health Science Center Foundation of Syracuse</td>
<td>PPS as a biomarker for tumor development and progression</td>
<td>ACTIVE</td>
<td>01-Jan-2018</td>
<td>31-Dec-2018</td>
<td>3,000.00</td>
<td>3,000.00</td>
</tr>
<tr>
<td>Monteleone, Philip</td>
<td>110 Pediatrics</td>
<td>Children's Hospital of Philadelphia</td>
<td>NIH ROI Support: ACET11C2 Study</td>
<td>ACTIVE</td>
<td>02-Oct-2017</td>
<td>01-Oct-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Naqvi, Muhammad</td>
<td>110 Medicine</td>
<td>Bristol Myers Squibb Company</td>
<td>Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC</td>
<td>ACTIVE</td>
<td>29-Aug-2017</td>
<td>28-Aug-2018</td>
<td>9,250.00</td>
<td>9,250.00</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Institution</td>
<td>Summary</td>
<td>Status</td>
<td>Start Date</td>
<td>End Date</td>
<td>Grant Amount</td>
<td>Description</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------------</td>
<td>----------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Muhammad</td>
<td>110 Medicine</td>
<td>BioClin Therapeutics Incorporated</td>
<td>A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Dooxetawel Versus Placebo Plus Dooxetawel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma, . . .</td>
<td>ACTIVE</td>
<td>12-Dec-2017</td>
<td>11-Dec-2018</td>
<td>14,000.00</td>
<td>14,000.00</td>
</tr>
<tr>
<td>Neiman</td>
<td>110 Surgery - General</td>
<td>Draeger Medical Incorporated</td>
<td>Education Grant: Educating ICU clinicians on research findings concerning lung physiology, mechanical breath profiling, and use of various modes of ventilation with a focus on APRV</td>
<td>ACTIVE</td>
<td>01-Aug-2017</td>
<td>31-Jul-2018</td>
<td>55,000.00</td>
<td>55,000.00</td>
</tr>
<tr>
<td>Ost</td>
<td>110 Surgery - Orthopedics</td>
<td>National Inst of Arthritis Musculoskeletal &amp; Skin</td>
<td>Reducing Post-Radiation Bone Fragility Through Orchestrated Cell Survival</td>
<td>ACTIVE</td>
<td>01-Aug-2017</td>
<td>31-Jul-2018</td>
<td>356,400.00</td>
<td>1,782,000.00</td>
</tr>
<tr>
<td>Paslano,</td>
<td>110 Medicine</td>
<td>Visterra Incorporated</td>
<td>Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous Voxig (Voxilin) in Addition to OaQtamin (Tamiflu) Compared With OaQtamin Alone in Hospitalized Adults With Influenza A, . . .</td>
<td>ACTIVE</td>
<td>29-Nov-2017</td>
<td>28-Nov-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Perl</td>
<td>110 Medicine</td>
<td>EMD Serono Incorporated</td>
<td>A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Examining the Safety and Efficacy of MZ951 in Subjects with Systemic Lupus Erythematosus (SLE)</td>
<td>ACTIVE</td>
<td>04-Aug-2017</td>
<td>03-Aug-2018</td>
<td>15,500.00</td>
<td>15,500.00</td>
</tr>
<tr>
<td>Perl</td>
<td>110 Medicine</td>
<td>Celgene Corporation</td>
<td>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus</td>
<td>ACTIVE</td>
<td>11-Aug-2017</td>
<td>10-Aug-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Perl</td>
<td>110 Medicine</td>
<td>Aurinia Pharmaceuticals Incorporated</td>
<td>A Randomized, Controlled Double-Blind Study Comparing the Efficacy and Safety of Orivel (voseliporin) (21.7 mg Twice Daily) with Placebo in Achieving Remission in Subjects with Active Lupus Nephritis</td>
<td>ACTIVE</td>
<td>29-Aug-2017</td>
<td>28-Aug-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Perl</td>
<td>110 Medicine</td>
<td>NYS Department of Health</td>
<td>Lupus, Autoimmunity, Inflammation and Immune Health Center of Excellence (LACE)</td>
<td>ACTIVE</td>
<td>31-Dec-2017</td>
<td>30-Dec-2019</td>
<td>349,444.00</td>
<td>349,444.00</td>
</tr>
<tr>
<td>Pignoni, Francesca</td>
<td>110 Ophthalmology</td>
<td>National Eye Institute</td>
<td>Neural versus non-neural fate choice in the developing eye epithelium</td>
<td>ACTIVE</td>
<td>01-Sep-2017</td>
<td>31-May-2018</td>
<td>364,500.00</td>
<td>1,458,000.00</td>
</tr>
<tr>
<td>Poiesz, Bernard</td>
<td>110 Medicine</td>
<td>Calthera Biosciences Incorporated</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-689 in Combination with Evoxolimus (CBE) vs. Placebo with Eeroxilimus (PoTe) in Patients with Advanced or Metastatic Renal Cell Carcinoma (IRC)</td>
<td>ACTIVE</td>
<td>25-Oct-2017</td>
<td>24-Oct-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Sachdeva, Ramesh</td>
<td>110 Senior Vice President and Dean of the College of Medicine</td>
<td>Health Research Inc State Innovation Model: Round Two of Funding for Design and Test Assistance</td>
<td>State Innovation Model: Round Two of Funding for Design and Test Assistance</td>
<td>ACTIVE</td>
<td>01-Jan-2018</td>
<td>31-Jan-2019</td>
<td>175,000.00</td>
<td>175,000.00</td>
</tr>
<tr>
<td>Sanders, Amy</td>
<td>110 Neurology</td>
<td>Janssen Research and Development LLC</td>
<td>A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigation the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic at Risk for Developing Alzheimer’s Disease</td>
<td>ACTIVE</td>
<td>15-Nov-2017</td>
<td>24-Feb-2023</td>
<td>3,000.00</td>
<td>3,000.00</td>
</tr>
<tr>
<td>Setter, Kevin</td>
<td>110 Surgery - Orthopedics</td>
<td>OrthoSpace Limited</td>
<td>A prospective, single blinded, multi-center, randomized, controlled, pivotal study to assess the safety and effectiveness of the InSpace(TM) device for treatment of full thickness Massive Rotator Cuff Tears</td>
<td>ACTIVE</td>
<td>03-Sep-2017</td>
<td>31-Aug-2018</td>
<td>22,440.00</td>
<td>22,440.00</td>
</tr>
<tr>
<td>Shikoh, M</td>
<td>110 Pharmacology</td>
<td>Carol M. Baldwin Breast Cancer Research Fund Inc</td>
<td>Development of a natural product for breast cancer treatment</td>
<td>ACTIVE</td>
<td>01-Dec-2017</td>
<td>30-Nov-2019</td>
<td>50,000.00</td>
<td>50,000.00</td>
</tr>
<tr>
<td>Suryadevara,</td>
<td>110 Pediatrics</td>
<td>Janssen Research and Development LLC</td>
<td>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumictabine (JNJ-64041575) Regimens in Hospitalized . . .</td>
<td>ACTIVE</td>
<td>07-Dec-2017</td>
<td>06-Dec-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Suryadevara,</td>
<td>110 Pediatrics</td>
<td>Janssen Research and Development LLC</td>
<td>A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumictabine (JNJ-64041575) on the incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection</td>
<td>ACTIVE</td>
<td>13-Feb-2018</td>
<td>30-Oct-2021</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Taftarico,</td>
<td>110 Surgery - Orthopedics</td>
<td>VertiFlex Incorporated</td>
<td>Postmarket Superior Space Registry for Evaluation of Superior Space (PRESS)</td>
<td>ACTIVE</td>
<td>26-Jan-2018</td>
<td>25-Jan-2019</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Turk, Margaret</td>
<td>110 Rehabilitation Medicine</td>
<td>University of South Carolina</td>
<td>Coordinating Center for Research to Promote the Health of Children with Birth Defects and People with Developmental and Other Disabilities</td>
<td>ACTIVE</td>
<td>30-Sep-2017</td>
<td>29-Sep-2018</td>
<td>77,490.00</td>
<td>77,490.00</td>
</tr>
<tr>
<td>Viapiano, Mariano</td>
<td>110 Physiology</td>
<td>US Army Medical Research Acquisition Activity</td>
<td>Engineering T Cells Against the Tumor Extracellular Matrix for Enhanced Immunotherapy of Mesothelioma</td>
<td>ACTIVE</td>
<td>01-Aug-2017</td>
<td>14-Aug-2018</td>
<td>296,100.00</td>
<td>296,100.00</td>
</tr>
<tr>
<td>Wang, Guirong</td>
<td>110 Surgery - General</td>
<td>National Science Foundation</td>
<td>SCH: INT: Collaborative Research: Crowd in Action: Human-Centric Privacy-Preserving Data Analytics for Environmental Public Health</td>
<td>ACTIVE</td>
<td>01-Sep-2017</td>
<td>31-Aug-2018</td>
<td>259,000.00</td>
<td>259,000.00</td>
</tr>
<tr>
<td>Weiner, Leonard</td>
<td>110 Pediatrics</td>
<td>Merck Sharp and Dohme Corporation</td>
<td>A Phase III randomized, active-comparator-controlled clinical trial to study the safety and efficacy of MK-1986 (tedizolid phosphate) and comparator, in subjects 3 months to &lt;12 years of age with Acute Bacterial Skin and Skin Structure . . .</td>
<td>ACTIVE</td>
<td>01-Aug-2017</td>
<td>31-Jul-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Weiner, Leonard</td>
<td>110 Pediatrics</td>
<td>Merck Sharp and Dohme Corporation</td>
<td>A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Cefitazidime/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects with Complicated Urinary Tract . . .</td>
<td>ACTIVE</td>
<td>20-Nov-2017</td>
<td>19-Nov-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Weiner, Leonard</td>
<td>110 Pediatrics</td>
<td>Merck Sharp and Dohme Corporation</td>
<td>A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Cefitazidime/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects . . .</td>
<td>ACTIVE</td>
<td>20-Nov-2017</td>
<td>19-Nov-2018</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Name</td>
<td>Department</td>
<td>Institution</td>
<td>Study Title</td>
<td>Status</td>
<td>Start Date</td>
<td>End Date</td>
<td>Amount</td>
<td>Total</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------</td>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------</td>
<td>----------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Weiner, Leonard</td>
<td>Pediatrics</td>
<td>Merck Sharp and Dohme Corporation</td>
<td>A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II</td>
<td>ACTIVE</td>
<td>05-Jan-2018</td>
<td>04-Jan-2019</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>Weinstock, Ruth</td>
<td>Medicine</td>
<td>Jaeb Center for Health Research Incorporated</td>
<td>CGM Intervention in Teens and Young Adults with T1D (CITY)</td>
<td>ACTIVE</td>
<td>01-Sep-2017</td>
<td>31-Dec-2019</td>
<td>5,500.00</td>
<td>5,500.00</td>
</tr>
<tr>
<td>Weinstock, Ruth</td>
<td>Medicine</td>
<td>Mylan Incorporated</td>
<td>A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients</td>
<td>ACTIVE</td>
<td>07-Dec-2017</td>
<td>06-Dec-2018</td>
<td>5,050.00</td>
<td>5,050.00</td>
</tr>
<tr>
<td>Wojcikiewicz, Richard</td>
<td>Pharmacology</td>
<td>University of Virginia</td>
<td>Role of EZH2 in myelofibrosis</td>
<td>ACTIVE</td>
<td>01-Sep-2017</td>
<td>31-May-2018</td>
<td>28,125.00</td>
<td>28,125.00</td>
</tr>
</tbody>
</table>